A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD⁺) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD). This study was part of the ChromaDex External Research Program (CERP), which donated ChromaDex’s patented NR ingredient, Niagen, the most efficient and high quality NAD⁺ precursor, for the advancement of this research.

In a pioneering development for PD treatment, this landmark phase I randomized, double-blind clinical study reported in the peer-reviewed journal Nature Communications by a team of scientists led by Prof. Charalampos Tzoulis, Haukeland University Hospital and University of Bergen in Norway, demonstrated that supplementing individuals with PD with high-dose (3,000 mg daily) Niagen NR was short-term safe, greatly increased whole blood NAD⁺ levels, augmented the NAD⁺ metabolome, and was associated with a significant clinical improvement. These results build upon previous research led by Dr. Tzoulis (Cell Metabolism) and showcase that supplementation with Niagen NR may be a therapeutic strategy for PD, pending further research.

With several studies demonstrating the safety and tolerability of 2,000mg of Niagen NR, this marks a milestone as the first-ever clinical study to demonstrate the safety, tolerability, and beneficial effects of high-dose Niagen NR at 3,000 mg per day.

“As the world's leading company in NAD⁺ research and commercialization, ChromaDex is proud to announce this groundbreaking NR-SAFE study from Dr. Tzoulis and his team of researchers that reveals the potential of Niagen NR as a therapy for Parkinson's disease. PD affects more than 10 million people worldwide,” noted Rob Fried, CEO of ChromaDex. “This research not only demonstrates the safety and tolerability of high-dose Niagen NR but also highlights its ability to significantly increase NAD⁺ levels and potentially improve the clinical severity of PD."

PD is a common neurodegenerative disorder largely characterized by progressive impairments in motor function, including tremors, stiffness, slow movement, and poor balance, as well as in non-motor functions, such as abnormal sleep patterns, gastrointestinal dysfunction, and cognitive impairment, or dementia. Current treatment options are limited, and there is a pressing need for innovative approaches to manage the effects of this debilitating neurodegenerative disorder.